At CYTOO, we’ve extended our micropatterning technology beyond muscle biology (MyoScreen™) to create a breakthrough in kidney research: engineered proximal tubule epithelial tubes that replicate human tubulogenesis in vitro.
Why this matters for drug development:
- Physiologically relevant expression and localization of key transporters (GGT1, Megalin, OCT2)
- Enhanced sensitivity to nephrotoxic compounds like gentamicin—even at clinically relevant low doses
- Early detection of toxicity-related morphological changes before functional damage
The impact:
This isn’t just another cell model. It’s a validated platform that bridges the gap between 2D cultures and animal models, offering predictive power when it matters most – before costly clinical trials.
This study highlights CYTOO technology as a versatile platform offering more physiologically relevant kidney models for drug safety and discovery.
📄See full publication
